Study suggests dexmedetomidine before surgery reduced remifentanil-induced hyperalgesia

April 12, 2013, American Academy of Pain Medicine

Surgical patients who demonstrated heightened pain sensitivity, or hyperalgesia, induced by high doses of a synthetic opioid had their symptoms alleviated by co-treatment with dexmedetomidine, according to new research. Study investigators, who presented their results today at the 29th Annual Meeting of the American Academy of Pain Medicine, concluded that dexmedetomidine may be a new and effective treatment option for opioid-induced hyperalgesia (OIH).

OIH refers to increased due to high-dose or prolonged opioid exposure. is an alpha-2 adrenergic agonist that is believed, based on prior research, to reduce pain and opioid requirements after surgery (Blaudszun et al, Anesthesiology 2012;116(6):1312-22). In the current study, OIH was induced by high doses of remifentanil, which is an ultra short-acting synthetic opioid used during surgery as an adjunct to anesthesia and to relieve pain.

"High-dose remifentanil can induce hyperalgesia, which is marked by a decreased mechanical hyperalgesia threshold, enhanced , shorter time to first postoperative analgesic requirement and greater morphine consumption," said Kim Yeon-Dong, MD, lead study author and a clinical professor of anesthesiology and pain medicine at Wonkwang University Hospital in Iksan City, South Korea. "Dexmedetomidine infusion efficiently alleviated these symptoms."

Patients treated with dexmedetomidine reported less pain, used less post-surgical morphine, and went longer before requesting medication for pain relief than patients treated with placebo. They also reported fewer adverse opioid-related effects, including nausea.

The research was conducted on 90 patients who underwent laparoscopically-assisted . Patients were randomly assigned to 1 of 3 research groups, each of which received either dexmedetomidine or placebo saline 15 minutes before surgery. During surgery, all patients received a remifentanil infusion.

Group C received placebo and a comparatively low dose (0.05 µg/kg/min) of remifentanil. The next 2 groups received higher doses of remifentanil: group RH received placebo and 0.3 µg/kg/min remifentanil; and group DRH received dexmedetomidine and 0.3 µg/kg/min remifentanil.

Patients in the RH group, who were treated with placebo and high-dose remifentanil, had a lower threshold for mechanical in the 24 hours after surgery than the other 2 groups and were the first to require analgesia for pain. The same placebo group also had more pain intensity and greater use of patient-controlled morphine for pain than group DRH, which received dexmedetomidine and high-dose remifentanil. Additionally, group DRH reported less shivering and postoperative nausea and vomiting than the other 2 groups. All findings were statistically significant.

Dr. Kim said those who might benefit from treatment with alpha-2 agonists include patients who are hospitalized for painful conditions or procedures and who have not responded to traditional medication.

Explore further: Anesthesia regimen linked to post-orthognathic op pain

Related Stories

Anesthesia regimen linked to post-orthognathic op pain

July 31, 2012
(HealthDay) -- Patients undergoing orthognathic maxillofacial surgery experience more pain postoperatively if they receive anesthesia with propofol and remifentanil versus inhalational agents and longer-acting opioids, according ...

Post-operative intravenous acetaminophen may help reduce use of morphine in infants

January 8, 2013
Among infants undergoing major surgery, postoperative use of intermittent intravenous paracetamol (acetaminophen) for the management of pain resulted in a lower cumulative morphine dose over 48 hours, according to a study ...

Cannabinoid formulation benefits opioid-refractory pain

June 13, 2012
(HealthDay) -- A novel cannabinoid formulation, nabiximols, is safe and effective for patients with advanced cancer and opioid-refractory pain, especially at a low-dose, according to a study published in the May issue of ...

Heroin addicts have higher pain sensitivity, even during treatment

April 25, 2012
(HealthDay) -- Heroin addicts often have an increased sensitivity to pain, and this sensitivity does not subside over the course of treatment with methadone or other opioids, new research finds.

Recommended for you

Patients receive most opioids at the doctor's office, not the ER

January 16, 2018
Around the country, state legislatures and hospitals have tightened emergency room prescribing guidelines for opioids to curb the addiction epidemic, but a new USC study shows that approach diverts attention from the main ...

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.